Elias Bjornson

Goeteborg, O, Sweden

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 74 publications

Angiopoietin-like protein 3 complete and partial deficiency markedly accelerates apolipoprotein B48 and B100 metabolism in triglyceride-rich lipoproteins in humans.

Angiopoietin-like protein 3 complete and partial deficiency markedly accelerates apolipoprotein B48 and B100 metabolism in triglyceride-rich lipoproteins in humans.

Journal: Journal of internal medicine

Published: June 11, 2026

Triglyceride-Rich Lipoproteins and ASCVD: Evidence for Causality and Challenges in Therapeutic Translation.

Triglyceride-Rich Lipoproteins and ASCVD: Evidence for Causality and Challenges in Therapeutic Translation.

Journal: Current atherosclerosis reports

Published: May 20, 2026

Risk-weighted apoB: the evidence on the scales.

Risk-weighted apoB: the evidence on the scales.

Journal: European heart journal

Published: April 09, 2026

Optimizing lipoprotein(a) testing for immediate clinical impact in primary prevention.

Optimizing lipoprotein(a) testing for immediate clinical impact in primary prevention.

Journal: Atherosclerosis

Published: April 07, 2026

Lipoprotein(a) - the hereditary risk factor for cardiovascular disease

Lipoprotein(a) - the hereditary risk factor for cardiovascular disease

Journal: Lakartidningen

Published: March 20, 2026

Triglyceride-rich lipoproteins, low-density lipoproteins, and risk of abdominal aortic aneurysm.

Triglyceride-rich lipoproteins, low-density lipoproteins, and risk of abdominal aortic aneurysm.

Journal: medRxiv : the preprint server for health sciences

Published: March 11, 2026

Apolipoprotein B-containing lipoproteins: distinct roles in atherosclerosis revealed by plasma proteomic profiling.

Apolipoprotein B-containing lipoproteins: distinct roles in atherosclerosis revealed by plasma proteomic profiling.

Journal: European heart journal

Published: February 28, 2026

Apolipoprotein C-III: Risk-factor, Regulator of Triglyceride-rich Lipoprotein Metabolism and Therapeutic Target.

Apolipoprotein C-III: Risk-factor, Regulator of Triglyceride-rich Lipoprotein Metabolism and Therapeutic Target.

Journal: Current atherosclerosis reports

Published: January 07, 2026

Clinical relevance of per-particle atherogenicity of triglyceride-rich lipoproteins, Lp(a) and LDL for cardiovascular risk.

Clinical relevance of per-particle atherogenicity of triglyceride-rich lipoproteins, Lp(a) and LDL for cardiovascular risk.

Journal: Pharmacology & therapeutics

Published: December 15, 2025

Association of Lipoprotein(a) With Coronary Atherosclerosis and Cardiovascular Events: Findings From the SCAPIS Cohort.

Association of Lipoprotein(a) With Coronary Atherosclerosis and Cardiovascular Events: Findings From the SCAPIS Cohort.

Journal: JACC. Cardiovascular imaging

Published: November 11, 2025

Coronary Computed Tomography Angiography in Prediction of First Coronary Events.

Coronary Computed Tomography Angiography in Prediction of First Coronary Events.

Journal: JAMA

Published: November 09, 2025

'Genetic modelling of triglyceride-rich lipoprotein/remnant lowering mimics APOC3-silencing and predicts clinically relevant coronary heart disease event reductions': author's response.

'Genetic modelling of triglyceride-rich lipoprotein/remnant lowering mimics APOC3-silencing and predicts clinically relevant coronary heart disease event reductions': author's response.

Journal: European journal of preventive cardiology

Published: October 24, 2025

Showing 1-12 of 74

Last Updated: 09/26/2026